

Ludwig Scientist(s)	Affiliation(s)	Keywords	Abstract/Presentation Category	Presentation/Abstract Title & Time
FRIDAY, NOVEMBER 10				
Arlene Sharpe (session chair)	Ludwig Harvard	N/A	Science Behind the Therapy: Mechanisms of Efficacy & Toxicity	Introduction (9:25 - 9:35am)
SATURDAY, NOVEMBER 11				
Michael Postow	Ludwig MSK	N/A	Clinical Management (Physician/Nurse/Pharmacy Track)	General Concepts of Toxicity Management (3:45 - 4:15pm)
Michael Postow	Ludwig MSK	N/A	Clinical Management (Physician/Nurse/Pharmacy Track)	Panel Discussion: Management of Complex Adverse Events (4:35 - 5:00pm)
SUNDAY, NOVEMBER 12				
Crystal Mackall	Ludwig Stanford	N/A	Genetically Modified Cell Therapy	Updates in CAR T cells (8:30 - 8:55am)
Michael Postow	Ludwig MSK	N/A	Hot Topic Symposium: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy?	Emerging Topics (10:55 - 11:15am)
Michael Postow	Ludwig MSK	N/A	Hot Topic Symposium: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy?	Challenges in Clinical Development (11:15 - 11:35am)

*scientist is lead author

**scientist is senior author

ORAL PRESENTATIONS				
Ping-Chih Ho	Ludwig Lausanne	Myeloid cells Immune suppression Metabolism Monocyte/Macrophage Tumor infiltrating lymphocytes (TILs) Tumor microenvironment	Cellular Metabolism and Antitumor Immunity	Re-educating macrophage through glutamine metabolism-mediated metabolic and epigenetic reprogramming
Michael Postow*, Jedd Wolchok	Ludwig MSK	Checkpoint blockade Clinical trial Solid tumors	Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)	Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma
Stephen Kron*	Ludwig Chicago	Tumor infiltrating lymphocytes (TILs) T cell Solid tumors Biomarkers Immune contexture Tumor microenvironment Targeted therapy Antibody Checkpoint blockade Radiotherapy	Emerging Models and Imaging	Multiplex three-dimensional optical mapping of tumor immune microenvironment
ABSTRACTS				
Sunita Hack, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus	Clinical Trials Management Team	Antibody Solid tumors Checkpoint blockade TLR Tumor microenvironment Tumor infiltrating lymphocytes (TILs) Clinical trial	Clinical Trials - in progress	Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors

*scientist is lead author

**scientist is senior author

Sadna Budhu*, Rachel Giese, Roberta Zappasodi, Luis Felipe Campesato, Aditi Gupta, Jedd Wolchok, Taha Merghoub**	Ludwig MSK	Checkpoint blockade Radiotherapy Tumor infiltrating lymphocytes (TILs) Solid tumors	Combination Therapy	Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma
Bianca Santomaso*, Margaret Callahan**	Ludwig MSK	Checkpoint blockade	irAE Management: Clinical Care and Best Practices	Neurotoxicity in patients with metastatic solid tumors treated with immune checkpoint inhibitors: a single institution retrospective analysis
Jennifer Guerriero*, Sara Schad, Anthony Letai**	Ludwig Harvard	Antigen presenting cells Costimulation Myeloid cells Tumor microenvironment Monocyte/Macrophage Solid tumors	Tumor Microenvironment (Mechanisms and Therapies)	Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis
Dmitriy Zamarin*, Anton Oseledchik, Mathieu Gigoux, Taha Merghoub, Jedd Wolchok**	Ludwig MSK	Checkpoint blockade Tumor microenvironment Vaccine	Oncolytic Viruses and Intratumoral Therapies	Upregulation of PD-L1 in tumor microenvironment is a resistance mechanism for oncolytic virus immunotherapy
Roberta Zappasodi*, Sadna Budhu, Michael Postow, Cailian Liu, Hong Zhong, Billel Gasmi, Daniel Hirschhorn-Cymerman, Taha Merghoub, Jedd Wolchok**	Ludwig MSK	Biomarkers Checkpoint blockade Immune monitoring Immune suppression T cell Tumor evasion	Mechanisms of Resistance to Immunotherapy	Non-conventional inhibitory CD4+ Foxp3- PD-1 hi T cells as a biomarker of immune checkpoint blockade activity

*scientist is lead author

**scientist is senior author

Daniel Hirschhorn*, Bilel Gasmi, Levi Mark Mangarin, Sadna Budhu, Yang Xia, Hong Zhong, Cailian Liu, Roberta Zappasodi, Jedd Wolchok, Taha Merghoub**	Ludwig MSK	Immune adjuvant Solid tumors Immune toxicity Tumor stroma Tumor microenvironment	Immune Modulation, Cytokines, and Antibodies	T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
Hyejin Choi*, Tarik Silk, Taha Merghoub, Jedd Wolchok	Ludwig MSK	Checkpoint blockade Targeted therapy T cell	Combination Therapy	Optimizing targeted therapy and immune checkpoint blockade therapy in Kras mutant lung cancer
Aditi Gupta*, Sadna Budhu, Rachel Giese, Gerd Ritter, Jedd Wolchok, Taha Merghoub**	Ludwig MSK	Tumor microenvironment Targeted therapy Solid tumors Cytokine Antibody Immune suppression	Immune Modulation, Cytokines, and Antibodies	Isoform specific TGF- β inhibition in combination with radiation therapy as a novel immune therapeutic approach to cancer therapy
Luis Felipe Campesato*, Sadna Budhu, Jedd Wolchok, Taha Merghoub	Ludwig MSK	Tumor microenvironment Metabolism Solid tumors Tumor infiltrating lymphocytes (TILs)	Cellular Metabolism and Antitumor Immunity	T-cell metabolic insufficiency explains the dysfunctional immune response in renal cell carcinoma
Dominique Vanhecke, George Coukos, Laurent Derré, Camilla Jandus**	Ludwig Lausanne	Cytokine Leukemia/Lymphoma Tumor microenvironment Carcinogenesis MDSC NK/NK T cell	Cellular Metabolism and Antitumor Immunity	Tumor-derived PGD2 and Nkp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis in acute promyelocytic leukemia
Philip Greenberg*	Ludwig Scientific Advisory Committee	Adoptive immunotherapy Tumor microenvironment Solid tumors T cell Immune suppression Tumor antigens	Cellular Therapy Approaches	Engineering adoptive T cell therapy for efficacy in ovarian cancer

*scientist is lead author

**scientist is senior author

Michael Postow, Jedd Wolchok**	Ludwig MSK	Checkpoint blockade Clinical study Solid tumors Tumor microenvironment Chemotherapy Clinical trial Monocyte/Macrophage	Clinical Trials - in progress	Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors
--------------------------------	------------	--	-------------------------------	--

*scientist is lead author

**scientist is senior author